Ignite Creation Date:
2025-12-24 @ 9:56 PM
Ignite Modification Date:
2026-01-01 @ 12:21 AM
Study NCT ID:
NCT04730232
Status:
UNKNOWN
Last Update Posted:
2021-10-29
First Post:
2021-01-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
Sponsor:
Tianjin Medical University Second Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-12-27
Start Date Type:
ACTUAL
Primary Completion Date:
2024-02
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-07
Completion Date Type:
ESTIMATED
First Submit Date:
2021-01-25
First Submit QC Date:
None
Study First Post Date:
2021-01-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-10-22
Last Update Post Date:
2021-10-29
Last Update Post Date Type:
ACTUAL